Biosimilars are biologic medicines that have been approved by regulatory authorities as highly similar to the original, already-approved brand version (or its reference product). This means there are no clinically meaningful differences between the biosimilar and the approved biologic product in terms of safety, purity and potency. Biosimilars offer an opportunity to provide a more affordable alternative to biologics and are used to treat serious diseases, such as certain kinds of cancer, autoimmune disorders and diabetes.
Mylan has one of the largest and most diverse portfolios of biosimilars and insulin analogs in the industry with 20 products on the market or in development and regulatory approvals for biosimilars in more than 65 countries.
Biosimilar medicines fill an urgent, unmet need for more alternatives to biologic therapies on the market. These important options aim to bring competition, increase access and provide savings for patients and the overall healthcare system.
To learn more, visit Mylan’s Biosimilars Without Borders website.
DOP: August 2019